BVX - Bovie Medical Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
6.48
+0.07 (+1.09%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close6.41
Open6.49
Bid0.00 x 1000
Ask0.00 x 2200
Day's Range6.35 - 6.71
52 Week Range2.28 - 7.70
Volume129,549
Avg. Volume213,712
Market Cap215.159M
Beta (3Y Monthly)N/A
PE Ratio (TTM)3.27
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire2 months ago

    Bovie Medical Corporation Files 510(k) Submission with the FDA for a New Indication to Market and Sell J-Plasma/Renuvion for Use in Dermal Resurfacing Procedures

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today announced a Premarket Notification 510(K) submission to the U.S. Food and Drug Administration (FDA) for a new indication for J-Plasma/Renuvion for use in dermal resurfacing procedures. “We are pleased to announce this 510(K) submission requesting clearance for a new clinical indication to market and sell our Renuvion Cosmetic Technology for dermal resurfacing procedures, which represents another important step towards our strategic objective to expand Renuvion’s clinical indications for use in the cosmetic surgery market,” said Charlie Goodwin, Chief Executive Officer.

  • Business Wire2 months ago

    Bovie Medical Corporation Announces Appointment of Tara H. Semb as Chief Financial Officer

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today announced the appointment of Tara H. Semb as Chief Financial Officer, effective January 2, 2019. “I am pleased to announce the appointment of Tara Semb, who joins the executive leadership team at Bovie Medical with a strong background in financial and operational business process and internal controls,” said Charlie Goodwin, President and Chief Executive Officer. “Ms. Semb’s career history includes executive level experience as the Chief Financial Officer for a rapidly growing company in the consumer market, and she has also held senior positions on the finance team at a large, diversified global manufacturing company with significant commercial scale and profitability.

  • Business Wire2 months ago

    Bovie Medical Corporation Announces Corporate Name Change to Apyx Medical Corporation and Plans to Transition Common Stock Listing to NASDAQ Global Select Market

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion® Cosmetic Technology brand in the cosmetic surgery market, today announced a corporate rebranding and company name change to Apyx Medical Corporation effective January 1, 2019. The Company also announced plans to move its stock exchange listing to the NASDAQ Global Select Market (the “NASDAQ”) from the New York Stock Exchange (the “NYSE”). The Company expects that its common stock will commence trading on the NASDAQ Global Select Market on January 2, 2019, under a new ticker symbol – “APYX”.

  • Business Wire3 months ago

    Bovie Medical Corporation Announces Future Retirement of Jay D. Ewers, Chief Financial Officer, Treasurer and Secretary

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that Jay D. Ewers, Chief Financial Officer, Treasurer and Secretary, intends to retire. The Company has initiated a search for a new Chief Financial Officer and Mr. Ewers is committed to remaining in his current role until a successor is found. “I would like to thank Jay, on behalf of the Board and the entire team at Bovie Medical, for his significant contributions since joining the Company in 2014,” said Charlie Goodwin, President and Chief Executive Officer.

  • Business Wire4 months ago

    Bovie Medical Corporation Reports Third Quarter 2018 Financial Results and Updates Fiscal Year 2018 Outlook

    Advanced Energy Sales of $3.0 million in Q3, up 40% year-over-year and 92% year-to-date

  • Business Wire4 months ago

    Bovie Medical Corporation to Participate in the 9th Annual Craig-Hallum Alpha Select Conference

    Bovie Medical Corporation , a medical technology company and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that management will participate in the 9th Annual Craig-Hallum Alpha Select Conference at the Sheraton New York Times Square Hotel in New York, New York.

  • Business Wire4 months ago

    Bovie Medical Corporation Announces Appointment of Laura Iversen as Director of Global Operations for Advanced Energy

    Bovie Medical Corporation (BVX) (the “Company”), a medical technology company and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the appointment of Laura Iversen as Director of Global Operations for Advanced Energy. “Bovie Medical is pleased to announce the appointment of Laura Iversen to this newly created leadership position, as we continue to focus on improving our manufacturing capabilities and efficiencies to accommodate the strong demand that we anticipate for our Advanced Energy products in the years to come,” said Charlie Goodwin, Chief Executive Officer of the Company.

  • Business Wire5 months ago

    Bovie Medical Corporation to Release Third Quarter of Fiscal Year 2018 Financial Results on November 1, 2018

    Bovie Medical (BVX), a medical technology company and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that financial results for the third quarter of fiscal year 2018 will be released after the market closes on Thursday, November 1. To listen to the call by phone, interested parties may dial 844-507-6493 (or 647-253-8641 for international callers) and provide access code 6375776. Participants should ask for the Bovie Medical Corporation Call.

  • Business Wire5 months ago

    Bovie Medical Corporation to Present at the Sidoti & Company Fall 2018 Investor Conference

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that management will participate in the Sidoti & Company Fall 2018 Investor Conference at the Grand Hyatt in New York, New York. A live audio webcast of the presentation will be provided under the ‘Company Events’ section of the Bovie Medical investor relations website at http://www.boviemedical.com/investor_relations/.

  • Business Wire6 months ago

    Bovie Medical Corporation Updates Fiscal Year 2018 Financial Outlook

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today updated financial guidance expectations for the twelve months ending December 31, 2018. The Company is introducing fiscal year 2018 financial guidance on a continuing operations basis as adjusted, which reflects the consummation of the Core segment sale transaction which closed on August 30, 2018. Total revenue from continuing operations in the range of $15.2 million to $15.6 million, representing growth of 49% to 53% year-over-year, compared to total revenue from continuing operations of $10.2 million in fiscal year 2017.

  • Business Wire6 months ago

    Bovie Medical Corporation Announces Completion of “Core” Business Segment Sale to Symmetry Surgical, Inc. for Total Cash Consideration of $97 Million

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that it has completed the previously announced divestiture and sale of the Core business segment and the Bovie® brand to Symmetry Surgical, Inc. for gross proceeds of $97 million in cash. Bovie Medical shareholders voted to approve the divestiture and sale transaction at an annual meeting of shareholders held on August 30, 2018.

  • Business Wire7 months ago

    Bovie Medical Corporation Reports Second Quarter 2018 Financial Results

    Advanced Energy Sales of $3.1 million in Q2, up 72% year-over-year

  • Business Wire7 months ago

    Bovie Medical Corporation to Release Second Quarter of Fiscal Year 2018 Financial Results on August 1, 2018

    Bovie Medical (BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that financial results for the second quarter of fiscal year 2018 will be released after the market closes on Wednesday, August 1. Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma® (marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market), a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue.

  • Business Wire8 months ago

    Bovie Medical Corporation Announces Agreement to Sell “Core” Business Segment to Symmetry Surgical, Inc. for Total Cash Consideration of $97 million

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that the Company has entered into a definitive agreement with Specialty Surgical Instrumentation Inc., a subsidiary of Symmetry Surgical Inc. (“Symmetry”), pursuant to which the Company will divest and sell the Core business segment and the Bovie® brand to Symmetry for gross proceeds of $97 million in cash. The asset purchase agreement was approved by the Company’s Board of Directors and is subject to customary closing conditions – including approval by the Company’s stockholders – and expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

  • Business Wire8 months ago

    Bovie Medical Corporation Announces Preliminary Second Quarter 2018 Revenue Results

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced preliminary revenue results for the second quarter of fiscal year 2018.

  • Business Wire9 months ago

    Bovie Medical Corporation to Participate in the JMP Securities 2018 Life Science Conference

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced that management will participate in the JMP Securities 2018 Life Science Conference at the St. Regis New York in New York, New York. A live audio webcast of the presentation will be provided under the ‘Company Events’ section of the Bovie Medical investor relations website at http://www.boviemedical.com/investor_relations/. Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma® (marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market), a patented plasma-based surgical product for cutting, coagulation and ablation of soft tissue.

  • ACCESSWIRE9 months ago

    Wired News - Microbot Medical Shares Results from the In-Vitro Study of its Self-Cleaning Shunt

    LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Microbot Medical Inc. (NASDAQ: MBOT), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=MBOT as the Company's latest news hit the wire. On May 21, 2018, the medical device Company, which is specializing in the design and development of transformational micro-robotic medical technologies, declared the results of its pre-clinical study evaluating the Company's Self-Cleaning Shunt (SCS). Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Microbot Medical.

  • ACCESSWIRE9 months ago

    Blog Exposure - Valeritas Presented Positive Clinical Results from Two New Studies Assessing V-Go Wearable Insulin Delivery Device in Type-2 Diabetes

    LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want access to our free research report on Valeritas Holdings, Inc. (NASDAQ: VLRX), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=VLRX as the Company's latest news hit the wire. On May 18, 2018, the Company reported positive results from two new studies assessing its V-Go Wearable Insulin Delivery device, during poster presentations at the American Association of Clinical Endocrinologists Annual Scientific and Clinical Congress held in Boston, Massachusetts. Active-Investors.com is currently working on the research report for Bovie Medical Corporation (NYSE AMER: BVX), which also belongs to the Healthcare sector as the Company Valeritas Holdings.

  • Business Wire9 months ago

    Bovie Medical Corporation Reports First Quarter 2018 Financial Results; Reaffirms Fiscal Year 2018 Financial Outlook

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today reported financial results for its first quarter ended March 31, 2018.

  • Business Wire9 months ago

    Bovie Medical Corporation Announces Completion of Enrollment in J-Plasma®/RenuvionTM Dermal Resurfacing Study

    Bovie Medical Corporation (BVX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the completion of enrollment for the U.S. Investigational Device Exemption (IDE) clinical study of its J-Plasma/Renuvion technology for use in dermal skin resurfacing. “We are excited to announce that today we have enrolled the final patient in our dermal skin resurfacing study, which represents another important development in our strategy to build clinical support for our Renuvion technology and expand its clinical indications for use in the cosmetic surgery market,” said Charlie Goodwin, Chief Executive Officer.

  • ACCESSWIRE9 months ago

    Bovie Medical Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2018 / Bovie Medical Corporation (NYSE American: BVX ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 14, 2018 at 4:30 PM Eastern ...

  • Business Wire10 months ago

    Bovie Medical Corporation Announces Appointment of Diane I. Duncan, M.D., FACS to Medical Advisory Board

    Bovie Medical Corporation (BVX) (the "Company"), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under the Renuvion™ Cosmetic Technology brand in the cosmetic surgery market, today announced the appointment of Diane I. Duncan, M.D., FACS to the Company’s Medical Advisory Board. “Dr. Duncan joins our Medical Advisory Board with over 30 years of experience in private practice as a plastic surgeon,” said Charlie Goodwin, Chief Executive Officer.

  • Business Wire10 months ago

    Bovie Medical Corporation to Release First Quarter of Fiscal Year 2018 Financial Results on May 14, 2018

    Bovie Medical , a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, today announced that financial results for the first quarter of fiscal year 2018 will be released after the market closes on Monday, May 14.

  • Business Wire11 months ago

    Bovie Medical Corporation Announces Launch of Renuvion™: A New Brand Dedicated to the Cosmetic Surgery Market

    Bovie Medical Corporation , a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product, today announced the launch of Renuvion™, a new brand that is dedicated to the cosmetic surgery market.